Chemistry:Entinostat
From HandWiki
![]() | |
Names | |
---|---|
Preferred IUPAC name
(Pyridin-3-yl)methyl ({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate | |
Other names
SNDX-275; MS-275
| |
Identifiers | |
3D model (JSmol)
|
|
ChEBI | |
ChEMBL | |
ChemSpider | |
KEGG | |
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
C21H20N4O3 | |
Molar mass | 376.4085 g/mol |
Pharmacology | |
1=ATC code }} | L01XH05 (WHO) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
![]() ![]() ![]() | |
Infobox references | |
Tracking categories (test):
Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers.[1]
Entinostat inhibits class I HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, respectively.[2]
Syndax pharmaceuticals currently holds the rights to entinostat and recently received $26.6 million in funds to advance treatments of resistant cancers using epigenetic tools.[3]
References
![]() | Original source: https://en.wikipedia.org/wiki/Entinostat.
Read more |